TransCode公司TTX-MC138进入ctDNA阳性结直肠癌IIa期临床开发阶段

美股速递
Jun 03

TransCode Therapeutics公司的在研疗法TTX-MC138,在针对循环肿瘤DNA(ctDNA)阳性结直肠癌的临床研究中取得重要进展,现已推进至IIa期开发阶段。这一进展标志着该疗法在探索性治疗领域迈出了关键一步,旨在为特定患者群体提供新的潜在治疗选择。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10